IP Library Granted Patent US 8,609,865
Granted Patent B2
US 8,609,865 · App. 13/175,342 · Granted Dec 17, 2013

Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid

Inventors: Luigi Anzalone (West Chester, PA); Frank J. Villani (Perkasie, PA); Christopher A. Teleha (Fort Washington, PA); Penina Feibush (Ambler, PA); Barry Fegely (Quakertown, PA)
Assignee: Furiex Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,609,865
App. No.
13/175,342
Granted
Dec 17, 2013
Kind
B2
Abstract

The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.

Claims (14)

1. A method of preparing a crystalline zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid comprising the steps of:

combining a strong ionizable acid with 5-({[2-tert-butoxycarbonylamino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1 H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid to prepare a salt of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1 H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid;

washing said salt of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino }-methyl)-2-methoxy-benzoic acid with an inorganic base to obtain the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid; and

crystallizing the zwitterion wherein the crystallizing comprises storing the zwitterion at a relative humidity of between about 0 to about 40% or at greater than about 60%.

2. The method of claim 1 , further comprising the step of washing said zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid with water.

3. The method of claim 1 , wherein said inorganic base is sodium hydroxide.

4. The method of claim 1 , wherein said ionizable acid is hydrochloric acid and wherein said salt is the hydrochloride salt of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.

5. A method of preparing a crystalline zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid comprising the steps of:

combining hydrochloric acid with 5-({[2-tert-butoxycarbonylamino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxybenzoic acid to prepare the hydrochloride salt of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid;

washing said salt of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid with sodium hydroxide to obtain the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid;

washing said zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid with water; and

crystallizing the zwitterion wherein the crystallizing comprises storing the zwitterion at a relative humidity of between about 0 to about 40% or at greater than about 60%.

6. The method of claim 1 , wherein the crystalline zwitterion comprises a Form α crystal and crystallizing comprises storing the zwitterion at a relative humidity of between about 0 to about 40%.

7. The method of claim 1 , wherein the crystalline zwitterion comprises a Form β crystal and crystallizing comprises storing the zwitterion at a relative humidity of greater than about 60%.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2016
From: FOREST TOSARA LIMITED (F/K/A FOREST TOSARA UNLIMITED COMPANY)
To: ALLERGAN HOLDINGS UNLIMITED COMPANY
Reel/Frame 039897/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2016
From: FOREST TOSARA UNLIMITED COMPANY
To: ALLERGAN HOLDINGS UNLIMITED COMPANY
Reel/Frame 039370/0273 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2015
From: FURIEX PHARMACEUTICALS, LLC.
To: FURIEX HOLDINGS UNLIMITED COMPANY
Reel/Frame 036603/0168 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2015
From: FURIEX HOLDINGS UNLIMITED COMPANY
To: FOREST TOSARA LIMITED
Reel/Frame 036603/0236 →
CHANGE OF NAME Recorded Sep 18, 2015
From: FURIEX PHARMACEUTICALS, INC.
To: FURIEX PHARMACEUTICALS, LLC.
Reel/Frame 036640/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2013
From: ANZALONE, LUIGI; VILLANI, FRANK J.; TELEHA, CHRISTOPHER A.; FEIBUSH, PENINA; FEGELY, BARRY
To: JANSSEN PHARMACEUTICA, N.V.
Reel/Frame 031410/0014 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2013
From: JANSSEN PHARMACEUTICA, N.V.
To: FURIEX PHARMACEUTICALS, INC.
Reel/Frame 030469/0881 →
Continuity (3)
Division 12168331 · Jul 7, 2008
Provisional Application 60948584 · Jul 9, 2007
Related Publication 20110263868A1 · Oct 27, 2011